Value proposition

Pioneering RNA cell therapy for autoimmune disease

In November 2023, Selecta Biosciences Inc. (NASDAQ: SELB) merged with Cartesian Therapeutics to create a publicly traded company pioneering RNA cell therapy to treat autoimmune disease. The combined company will focus on advancing Cartesian’s wholly owned pipeline, including Descartes-08, Cartesian’s clinical-stage lead product candidate being evaluated in patients with myasthenia gravis and other autoimmune diseases. For more information about the company and updates, please visit https://www.cartesiantherapeutics.com/ or follow us on LinkedIn @Cartesian-Therapeutics.

Immunotherapy, Oncology, Molecular Biology, Immunology, Autoimmune Diseases, Myasthenia Gravis, ARDS, Cell Therapy, Lung disease, NETs, Cardiovascular Disease, Gene Therapy, Cancer Research, and multiple myeloma